REP 2165-Mg

REP 2165-Mg is a nucleic acid polymer (NAP) developed by Replicor Inc. for the treatment of chronic hepatitis B virus (HBV) and hepatitis D virus (HDV) infection. It is a magnesium chelate formulation of REP 2165, a phosphorothioate oligonucleotide designed to inhibit the assembly and release of hepatitis B surface antigen (HBsAg) subviral particles from infected hepatocytes. By clearing HBsAg from the circulation, REP 2165-Mg aims to restore the host's immunological control over the infection, a process often referred to as functional cure. REP 2165 is a derivative of the earlier compound REP 2139, engineered to maintain antiviral activity while exhibiting lower accumulation in the liver. The magnesium chelate formulation is utilized to improve the tolerability of intravenous administration. In clinical development, REP 2165-Mg is typically evaluated in combination with pegylated interferon alpha-2a and nucleos(t)ide analogues such as tenofovir disoproxil fumarate.